Difference between revisions of "Team:San Andres/Software"

Line 20: Line 20:
  
 
<body class="gwd-body-kwce">
 
<body class="gwd-body-kwce">
−
  <title>wiki</title>
 
−
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
 
−
  <meta name="generator" content="Google Web Designer 1.3.2.0521">
 
−
  <style type="text/css">
 
−
    html, body {
 
−
      width: 100%;
 
−
      height: 100%;
 
−
      margin: 0px;
 
−
    }
 
−
    body {
 
−
      -webkit-transform: perspective(1400px) matrix3d(1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1);
 
−
      -webkit-transform-style: preserve-3d;
 
−
      background-color: transparent;
 
−
    }
 
−
  </style>
 
 
   <meta http-equiv="content-type" content="text/html; charset=ISO-8859-1">
 
   <meta http-equiv="content-type" content="text/html; charset=ISO-8859-1">
 
   <title></title>
 
   <title></title>
Line 566: Line 551:
 
   <div class="gwd-div-2ed9"></div>
 
   <div class="gwd-div-2ed9"></div>
 
   <div class="gwd-div-7xzo gwd-a-1thu">
 
   <div class="gwd-div-7xzo gwd-a-1thu">
−
     <h1>Future Projections&nbsp;</h1>
+
     <h1>Collaborations</h1>
−
     <big>If our results are the expected our future projections are
+
     <big>So the project could be carried out we have the
−
the following:<br>
+
collaboration of two teams IGEM (<a href="https://2015.igem.org/Team:Colegio_EmelinaU">EmelinaU</a>
 +
and&nbsp;<a href="https://2015.igem.org/Team:Liceo_Eugenio_Hostos">Hostos</a>),
 +
since we work together in the same laboratory and share some parts of
 +
our Biobricks. We also have the contribution of teams <a href="https://2011.igem.org/Team:Washington">Washintong 2011</a>
 +
and&nbsp;<a href="https://2012.igem.org/Team:Colorado_State/Project">Colorado
 +
2012</a> , since their research served as references in our. <br>
 +
<br>
 
</big>
 
</big>
−
    <ul>
 
−
      <li><big>Be one of the first Latin American teams at the
 
−
school level in the IGEM competition.</big>
 
−
      </li>
 
−
      <li><big>Disclosure to the scientific community.</big>
 
−
      </li>
 
−
      <li><big>Realize workshops in academic institutions of
 
−
this enteropathy with the aim of being more known in society.</big>
 
−
      </li>
 
−
      <li><big>Generate the product and market it for
 
−
therapeutic purposes.</big>
 
−
      </li>
 
−
    </ul>
 
 
     <div style="text-align: center;">
 
     <div style="text-align: center;">
−
       <img src="https://static.igem.org/mediawiki/2015/3/3f/Igem.png" alt="igem.png" title="igem.png" style="width: 649px; height: 262px;">
+
       <img alt="https://static.igem.org/mediawiki/2015/e/e5/Grupo_800.jpg" src="https://static.igem.org/mediawiki/2015/e/e5/Grupo_800.jpg">
 
       <br>
 
       <br>
 
       <br>
 
       <br>
−
       <h1 style="text-align: left;">Business Model</h1>
+
       <h1 style="text-align: left;">References</h1>
−
       <div style="text-align: left;"><big>If all goes
+
       <div style="text-align: left;"><big>1.&nbsp;</big><big>Structural
−
well, we going to patenting our pill, which give us licenses which we
+
Basis for Gluten Intolerance in Celiac Sprue (2002)<br>
−
can sell to pharmacies and laboratories to produce the medication and
+
2. Seminar Coeliac Disease (2003)<br>
−
sell it to celiac patients. This would mean a social benefit and an
+
3.&nbsp;Mortality in celiac disease (2010)<br>
−
benefict for us.</big>
+
4.&nbsp;Crystallographic and Biochemical Investigations of
−
        <br>
+
Kumamolisin-As, a Serine-Carboxyl Peptidase with Collagenase Activity
−
        <br>
+
(2004)<br>
−
        <div style="text-align: center;">
+
5.&nbsp;Epilepsy, cerebral calcifications and clinical or
−
          <img alt="File:Business model.jpg" src="https://static.igem.org/mediawiki/2015/thumb/4/44/Business_model.jpg/755px-Business_model.jpg" height="600" width="755">
+
subclinical coeliac disease. Course and follow up with gluten-free diet
−
        </div>
+
(1998)<br>
 +
6.&nbsp;Coeliac disease on the rise in Europe (2010)<br>
 +
7.&nbsp;Should coeliac sufferers be allowed their oats? (2007)<br>
 +
8.&nbsp;Prevalence of Celiac Disease among Children in Finland
 +
(2001)<br>
 +
9.&nbsp;Protein engineering of improved prolyl endopeptidases for
 +
celiac sprue therapy (2008)<br>
 +
10. Undiagnosed coeliac disease and risk of autoimmune disorders in
 +
subjects with Type I diabetes mellitus (2001)<br>
 +
11.&nbsp;Analytical Methods for Detection of Gluten in Food—Method
 +
Developments in Support of Food Labeling Legislation (2011)<br>
 +
<span style="font-weight: bold;"></span></big>
 +
        <span style="font-family: &quot;Segoe UI&quot;,&quot;sans-serif&quot;;"></span>
 
       </div>
 
       </div>
 
     </div>
 
     </div>
−
    <big>
 
−
<br>
 
−
</big>&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;
 
 
     <br>
 
     <br>
 +
    <strong></strong>
 
   </div>
 
   </div>
 +
  <br>
 +
  <div class="gwd-div-a9c8"></div>
 +
  <br>
 
   <a href="https://2015.igem.org/Main_Page" class="gwd-a-3xpx gwd-a-36ww">
 
   <a href="https://2015.igem.org/Main_Page" class="gwd-a-3xpx gwd-a-36ww">
 
     <img style="border: 0px solid ; width: 150px; height: 150px; top: 35px; left: 989px;" alt="" src="https://static.igem.org/mediawiki/igem.org/6/60/Igemlogo_300px.png" class="gwd-img-kwqf">
 
     <img style="border: 0px solid ; width: 150px; height: 150px; top: 35px; left: 989px;" alt="" src="https://static.igem.org/mediawiki/igem.org/6/60/Igemlogo_300px.png" class="gwd-img-kwqf">
Line 613: Line 604:
 
   <br>
 
   <br>
 
   <br>
 
   <br>
−
   <div class="gwd-div-t5nw gwd-div-0zj6">
+
   <div class="gwd-div-t5nw gwd-div-6h0e">
 
     <style>
 
     <style>
 
       body {
 
       body {
Line 674: Line 665:
 
         -webkit-transform-style: preserve-3d;
 
         -webkit-transform-style: preserve-3d;
 
       }
 
       }
−
       .gwd-div-0zj6 {
+
       .gwd-div-6h0e {
−
         -webkit-transform: translate3d(-8.17px, -1631.31px, 0px);
+
         -webkit-transform: translate3d(-10.71px, -1585.71px, 0px);
 
         -webkit-transform-style: preserve-3d;
 
         -webkit-transform-style: preserve-3d;
 
       }
 
       }

Revision as of 00:59, 14 August 2015

wiki exp wiki wiki wiki 2   File:Gluten-s-Job.jpeg

Collaborations

So the project could be carried out we have the collaboration of two teams IGEM (EmelinaU and Hostos), since we work together in the same laboratory and share some parts of our Biobricks. We also have the contribution of teams Washintong 2011 and Colorado 2012 , since their research served as references in our.

https://static.igem.org/mediawiki/2015/e/e5/Grupo_800.jpg

References

1. Structural Basis for Gluten Intolerance in Celiac Sprue (2002)
2. Seminar Coeliac Disease (2003)
3. Mortality in celiac disease (2010)
4. Crystallographic and Biochemical Investigations of Kumamolisin-As, a Serine-Carboxyl Peptidase with Collagenase Activity (2004)
5. Epilepsy, cerebral calcifications and clinical or subclinical coeliac disease. Course and follow up with gluten-free diet (1998)
6. Coeliac disease on the rise in Europe (2010)
7. Should coeliac sufferers be allowed their oats? (2007)
8. Prevalence of Celiac Disease among Children in Finland (2001)
9. Protein engineering of improved prolyl endopeptidases for celiac sprue therapy (2008)
10. Undiagnosed coeliac disease and risk of autoimmune disorders in subjects with Type I diabetes mellitus (2001)
11. Analytical Methods for Detection of Gluten in Food—Method Developments in Support of Food Labeling Legislation (2011)